NAVLIN by EVERSANA

Last week, the Trump administration finalized two new “Most Favored Nation” (MFN) drug pricing agreements, sparking concern from Japan and Australia that the policy may already be impacting drug availability in their markets. In France, the draft 2026 Social Security Financing Bill (PLFSS) proposes revisions to the country’s early and direct access pathways for innovative medicines and introduces stricter controls on pharmaceutical rebates and clawbacks. Meanwhile, China’s 11th National Volume-Based Procurement (VBP) program will see 396 qualified bidders competing for roughly 3.7 billion drug doses, representing about 75% of hospital demand, this follows the postponement of the bidder application information disclosure meeting from October 21 to October 27. https://lnkd.in/dkj7bhNr #NAVLINDaily #DrugPricing #MFV #PLFSS #VBP

Struggling with Joint Clinical Assessment complexities? Start with PICO. Early planning helps avoid delays and ensures your evidence meets EU HTA expectations. Discover how: https://ow.ly/awXN50WPGv4. For more information about NAVLIN’s PICO Planner, contact us at info@navlin.com. #EVERSANA #JCA #PICOPlanning #HTAstrategy Shivani Shah

EMD Serono became the third major drugmaker to sign a “Most Favored Nation” pricing deal with the Trump administration, pledging to align U.S. drug prices with those in other wealthy nations and offer discounted IVF medications through the new TrumpRx program. In return, the company will receive a three-year tariff exemption and has been selected for the Commissioner’s National Priority Voucher (CNPV) pilot, under which it will submit its fertility drug, Pergoveris, for review. https://lnkd.in/debxSi7N #NAVLINDaily #PharmaPolicy #IVF #TrumpRx

China's 11th National Volume-based Procurement will see 396 bidders compete for nearly 3.7 billion doses of drugs, covering approximately 75% of hospital needs. Diprophylline injections is subject to the toughest competition, while AstraZeneca’s dapagliflozin leads in demand with over 460 million tablets. New rules from the National Healthcare Security Administration (NHSA) of China aim to strike a balance between affordability and quality, banning bids below production costs and requiring justification for prices. For the first time, hospitals can report drug demand by brand, allowing direct supply agreements. The policy has drawn more global players, such as Roche, AstraZeneca, Novartis, and Chugai, into the bidding process. https://lnkd.in/dbdQvJH9 #NAVLINDaily

France's draft 2026 Social Security Financing Bill (PLFSS 2026) aims to tighten rules on pharmaceutical rebates and clawbacks to better control healthcare costs. Article 10 introduces a new contribution structure for all companies marketing or distributing medicines in France, including those handling parallel imports. It also revises rebate procedures, requiring companies to make provisional quarterly payments to reduce cash flow delays in the national health insurance system. https://lnkd.in/dGF5CzV4 #NAVLINDaily #DrugPricing #MarketAccess #FrenchHealthcare

📈 Making Market Access Measurable with NAVLIN Insights KPI Discover how a global oncology leader transformed fragmented pricing data into a centralized KPI platform—unlocking real-time insights, faster decisions, and stronger strategic alignment across teams. - Centralized dashboards - Fast wins, long-term impact - KPI framework now shaping boardroom conversations 💡 From data to decisions—this is how launch excellence is done. 👉 Download the full case study: https://ow.ly/WUfc50X2al9 #MarketAccess #PharmaLaunch #EVERSANA #NAVLIN #Pricing #LifeSciences #KPI #DataDrivenStrategy #LaunchExcellence

(VBP) bidder application meeting from October 21 to October 27. This year’s bidding process allows selected suppliers to directly deliver drug demand by brand, an approach adopted by over 77% of 46,000 institutions. Since its launch in 2018, the VBP program has cut average drug prices by 50% and now covers 55 drug varieties, with safeguards in place to prevent below-cost bidding and ensure fairness and quality. https://lnkd.in/dvi667AG #NAVLINDaily #PharmaPolicy #APAC

Last week, the Trump administration announced plans to align 95% of U.S. prescription drugs with Trump’s Most Favored Nation (MFN) pricing by the end of his term. The UK government plans to raise the National Institute for Health and Care Excellence’s (NICE) quality-adjusted life year (QALY) threshold by 25%. Meanwhile, Costco partnered with Novo Nordisk to offer discounted Wegovy and Ozempic (semaglutide) to cash-paying customers. https://lnkd.in/dNzrGk8F #NAVLINDaily #HealthcarePolicy #PharmaNews

Strategic PICO Planning: A Game-Changer for Global Oncology Access Body: How do you navigate a saturated oncology market with confidence? With NAVLIN by EVERSANA, one biopharma leader did just that—leveraging country-specific PICOs, analog-based insights, and real-world evidence to meet HTA demands across Europe. This case study showcases how early, strategic planning can future-proof your development and drive smarter decisions across the asset lifecycle. Explore the insights: https://ow.ly/LG2q50X75Xj #MarketAccess #Oncology #HTA #PICO #RealWorldEvidence #PharmaStrategy Shivani Shah, Richard Wenzel, PhD

CMS Administrator Dr. Mehmet Oz stated that the Trump administration aims to align 95% of U.S. prescription drug prices with Most Favored Nation (MFN) levels by the end of Trump’s term. He also mentioned that the new TrumpRx direct-to-patient platform could provide benefits, such as coupons reimbursable through employers. Despite these measures, Oz emphasized that the administration will maintain a free-market approach and avoid direct price caps. https://ow.ly/B48Q50X9T5J #MostFavoredNation #DrugPricing #NavlinDaily #PharmaNews